Philip Morris   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (1847)
Status: No NME R&D (1847)

Organization Overview

First Clinical Trial
2009
NCT00894166
First Marketed Drug
2022
nicotine (nicorette)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

LLC Scientific Research Center Eco-Safety | Philip Morris Products SA | Philip Morris Products S.A. | Philip Morris USA, Inc.

Active Ingredients

Marketed Drugs (1)

Key: Philip Morris (0) Acquired (1)

nicotine (nicorette) (2022)

Drugs in Phase 3 Trials (3)

Key: Philip Morris (2) Acquired (1)

bupropion (wellbutrin) (4 trials)

nicotine (nicorette) (17 trials)

varenicline (chantix) (4 trials)

Drugs in Phase 2 Trials (2)

meclizine (antivert) (1 trial)

moclobemide (Amira) (1 trial)

Drugs in Other Trials (7)

gum (1 trial)

multivitamins (1 trial)

neoantigen reactive t cells (1 trial)

np2 (1 trial)

rabeprazole (pariet) (1 trial)

surufatinib (1 trial)

tobacco (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Tobacco Use Disorder (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 12